{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:30:15Z","timestamp":1789223415388,"version":"build-2803163510"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,9,21]]},"abstract":"<jats:p>\n            Multidrug-resistant\n            <jats:named-content content-type=\"genus-species\">Neisseria gonorrhoeae<\/jats:named-content>\n            has emerged as a threat to global health. The relationship between gepotidacin exposure and prevention of on-therapy amplification of drug-resistant\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            was examined using a 7-day hollow-fiber\n            <jats:italic>in vitro<\/jats:italic>\n            infection model. The study design included both inactive (no-treatment and ciprofloxacin) and active (ceftriaxone) control regimens. Study drug concentration-time profiles were simulated in the\n            <jats:italic>in vitro<\/jats:italic>\n            system for a single oral 0.\n          <\/jats:p>","DOI":"10.1128\/aac.00521-20","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T14:11:03Z","timestamp":1594735863000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber\n            <i>In Vitro<\/i>\n            Infection Model"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-1475","authenticated-orcid":false,"given":"Brian D.","family":"VanScoy","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":false,"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fikes","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Min","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Huang","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ingraham","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":false,"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Conde","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143304"},{"key":"e_1_3_2_4_2","first-page":"1","article-title":"Sexually transmitted infections and chlamydia screening in England, 2015","volume":"10","author":"Public Health England","year":"2016","unstructured":"Public Health England. 2016. Sexually transmitted infections and chlamydia screening in England, 2015. Health Prot Rep 10:1\u201327. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/534601\/hpr2216_stis.pdf.","journal-title":"Health Prot Rep"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002366"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics7030077"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ731"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_12_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. CLSI document M07-A11. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_13_2","volume-title":"Performance standards for antimicrobial susceptibility testing; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing; approved standard, 30th ed. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"30"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-18"},{"key":"e_1_3_2_16_2","first-page":"A177","article-title":"P3.225 Neisseria gonorrhoeae bacterial load differs between sample sites","volume":"93","author":"Van Der Veer B","year":"2017","unstructured":"Van Der Veer B, Dukers-Muijrers N, Hoebe C, Van Alphen L, Wolffs P. 2017. P3.225 Neisseria gonorrhoeae bacterial load differs between sample sites. Sex Transm Infect 93:A177\u2013A179.","journal-title":"Sex Transm Infect"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2016-052950"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01186-16"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05341-11"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.7.1825-1826.1994"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-13"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-16"},{"key":"e_1_3_2_23_2","unstructured":"Roche Laboratories Inc. 2004. Rocephin (ceftriaxone sodium) for injection (package insert). Roche Laboratories Inc. Nutley NJ."},{"issue":"03","key":"e_1_3_2_24_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski KA","year":"2015","unstructured":"Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64(RR-03):1\u2013137.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_2_25_2","unstructured":"Bayer HealthCare Pharmaceuticals Inc. 2016. Cipro (ciprofloxacin hydrochloride) package insert. Bayer HealthCare Pharmaceuticals Inc. Whippany NJ."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199411000-00009"},{"key":"e_1_3_2_27_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Hossain M","year":"2014","unstructured":"Hossain M, Tiffany CA, McDanald M, Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944, a novel topoisomerase inhibitor, abstr F-276. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00521-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00521-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:33:37Z","timestamp":1645486417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00521-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,21]]}},"alternative-id":["10.1128\/AAC.00521-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00521-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"2020-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00521-20"}}